PharmaCyte Biotech, Inc. (PMCB) stock
Close on Nov 11, 2026Market cap $4.28MP/E –Yield –
PharmaCyte Biotech, Inc. reported revenue of $0 for the twelve months to Apr 30, 2026. At the latest close the market valued the company at $4.28M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $4.28M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.16
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$19.42M
- EPS, diluted
- -$2.77
- Book value per share
- $2.56
- Diluted shares
- 11M
Trading
- Previous close
- $0.40
- Open
- $0.31
- Day's range
- $0.25 – $0.43
- Volume
- 1,268,851
- Average volume (20 days)
- 167,546
- Beta (5 years)
- 0.76
- 52-week range
- $0.25 – $1.51
- RSI (14 days)
- 56.4
- Volatility (1 year)
- 101.1%
- Relative volume
- 7.20×
- WACC
- 8.7%
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PMCB | S&P 500 | Difference | PMCB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.3% | -2.4% | +1.1 pts | ||
| 3 months | -27.5% | -1.2% | −26.3 pts | ||
| Year to date | -44.9% | +12.3% | −57.2 pts | ||
| 1 year | -54.6% | +12.4% | −67.0 pts | ||
| 3 years | -81.6% | +78.8% | −160.4 pts | -43.1% | +21.4% |
| 5 years | -85.6% | +75.2% | −160.8 pts | -32.2% | +11.9% |
| 10 years | -99.1% | +311.1% | −410.2 pts | -37.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases PharmaCyte Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
- News
About PharmaCyte Biotech
Biological Products, (No Diagnostic Substances)
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company that develops cellular therapies for the treatment of cancer. The company utilizes a proprietary cellulose-based live cell encapsulation platform called Cell-in-a-Box to produce treatments for various solid tumors. Its primary product candidate, CypCaps, consists of pinhead-sized porous capsules housing genetically modified human cells. These encapsulated cells are engineered to convert inactive cancer prodrugs into active chemotherapy agents directly at tumor sites, such as locally advanced, inoperable, non-metastatic pancreatic cancer. Because the company remains in the research and regulatory evaluation phase, its therapies are targeted toward oncology patients.
Company profile, executives and historyPharmaCyte Biotech stock: common questions
What is PharmaCyte Biotech's stock price?
PMCB closed at $0.40 on Nov 11, 2026, down 0.77% on the day. Over the past 52 weeks it traded between $0.25 and $1.51.
What is PharmaCyte Biotech's market cap?
PharmaCyte Biotech was worth $4.28M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PMCB's P/E ratio?
PharmaCyte Biotech lost money over the twelve months to Apr 30, 2026 (diluted EPS -$2.77), so it has no meaningful P/E ratio.
How much revenue does PharmaCyte Biotech make?
PharmaCyte Biotech reported revenue of $0 for the twelve months to Apr 30, 2026.
Does PharmaCyte Biotech pay a dividend?
No. PharmaCyte Biotech has not paid a cash dividend over the last twelve months.
How has PMCB stock performed over the past year?
Including dividends, PMCB returned -54.6% over the past year, against +12.4% for the S&P 500.
How many PMCB shares are sold short?
0M shares were sold short at the latest FINRA report, 0.51% of the float, or 1.2 days of average trading volume.
Who are PharmaCyte Biotech's competitors?
Companies most similar to PharmaCyte Biotech by business, industry and size include CLDI, SAEN, CRDF, AURA, CERO.
See a number that looks wrong?